WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: CHF2, Stimulation of adrenergic system, primarily norepinephrine . Increased HR and contractility, Increased Aldosterone . Salt and water retention, Increased HR and contractility . Increased myocardial oxygen use, Increased TNF and IL-6 . Myocardial hypertrophy, Stimulation of arterial chemoreceptors and baroreceptors and cardiopulmonary baroreceptors . Stimulation of reninangiotensin system, Increased peripheral vascular resistance . Increased Afterload, Stimulation of arterial chemoreceptors and baroreceptors and cardiopulmonary baroreceptors . Stimulation of adrenergic system, primarily norepinephrine, O2 @ 2lpm . Increased myocardial oxygen use, Increased preload . Increased cardiac output, Increased cardiac output . Ventricular remodeling, Ventricular remodeling . Progressive loss of cardiac output, Progressive loss of cardiac output . Stimulation of cytokine system, Increase Cardiac Output Albumin Human Levophed Neo-Synepharine . Increased cardiac output, Initial event that decreases pumping capacity . Stimulation of arterial chemoreceptors and baroreceptors and cardiopulmonary baroreceptors, Stimulation of adrenergic system, primarily norepinephrine . Increased peripheral vascular resistance, Increased peripheral vascular resistance . Decreased renal blood flow, Increased Angiotensin . Increased Aldosterone, Dialysis . Decreased renal blood flow, Stimulation of cytokine system . Increased TNF and IL-6, Salt and water retention Medication Increased preload